Upon the release of BioMarin's orphan drug Brineura, which made headlines for its $702,000-per-year price tag, chairman and CEO JJ Bienaimé said the system will have the final say on whether the sky-high price is fair. "Obviously, the system will have to determine that," he told Cramer on Friday. But I would say that CLN2, the disease that Brineura...